Brought to you by 
Deerfield wins sweetened bid to acquire NitroMed
03 Dec 2020
Executive Summary
After upping the ante twice, investment firm Deerfield Management has won its latest bid to acquire nitric oxide therapeutics biotech NitroMed for $0.80 in cash for each outstanding share--60% higher than its original offer--or about $36.8mm (over twice NitroMed's 2007 sales).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com